By Melane Sampson Michael J. Roberts, PhD, CEO and Co-founder of Adaptin Bio Adaptin Bio (OTCQB: APTN) is advancing a novel strategy to overcome one of the most persistent challenges in neuro-oncology—delivering...
Senti Biosciences (NASDAQ: SNTI) is developing a new generation of cell and gene therapies designed to bring greater precision, control, and safety to the treatment of difficult-to-treat cancers and other incurable...
OS Therapies (NYSE American: OSTX) is addressing the urgent need for innovative therapies to kill aggressive cancers that express HER2, including osteosarcoma—a rare and often fatal bone cancer—as well as other solid...
The nonprofit organization Healing the Hero is bringing hope to U.S. military personnel, veterans, first responders, and Gold Star Families by leveraging neurolinguistic programming (NLP)-informed methods to directly...
Closely held Siloton is developing a patented miniaturized medical imaging platform that combines photonic chips with optical coherence tomography (OCT) to detect and monitor a range of prevalent ophthalmic diseases...
Closely held Pacylex Pharmaceuticals is developing a first-in-class oral cancer therapy with a novel, broad mechanism of action designed for refractory cancers as both a monotherapy and a future combination therapy.
Closely held illumiSonics is addressing a significant unmet medical need by redefining tissue imaging with its proprietary multi-laser imaging (MLI) platform, an advanced modality designed for life sciences research...
Adagio Medical (NASDAQ: ADGM) is innovating catheter ablation technologies for the treatment of one of the most challenging and underserved areas in electrophysiology—ventricular tachycardia (VT), a dangerous type of...
Niagen Bioscience (NASDAQ: NAGE) is pioneering the research and development of nicotinamide adenine dinucleotide (NAD+)—a vital coenzyme essential to cellular metabolism, energy production, and DNA repair that declines...
MAIA Biotechnology (NYSE American: MAIA) is focusing on the development and commercialization of breakthrough telomere-targeting immunotherapies: potential first-in-class drugs with novel mechanisms of action that aim...